A phase 2a, open-label pilot study of the galectin-3 inhibitor GR-MD-02 for the treatment of moderate-to-severe plaque psoriasis

Autor:	Adam Allgood, Peter G. Traber, Harold Shlevin, Simon Ritchie, Danielle Neal
Rok vydání:	2017
Předmět:	0301 basic medicine Moderate to severe Plaque psoriasis medicine.medical_specialty business.industry Treatment outcome Follow up studies Dermatology medicine.disease Gastroenterology 03 medical and health sciences 030104 developmental biology Galectin-3 Psoriasis Maximum tolerated dose Internal medicine medicine Open label business
Zdroj:	Journal of the American Academy of Dermatology. 77:753-755
ISSN:	0190-9622
DOI:	10.1016/j.jaad.2017.05.055
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::dfceec177550c81c47f3b1fb1f107cf4 https://doi.org/10.1016/j.jaad.2017.05.055 Zobrazit plný text záznamu Full Text from ScienceDirect